Attended a Live Program?
Print Certificate
Publication Date: 07 February 2025
Glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) are effective treatments for weight loss and diabetes management. They reduce appetite and caloric intake by 16–39%. However, studies provide limited data on their impact on diet composition, eating patterns, and macronutrient or micronutrient intake. This video explores key findings from a narrative review, highlighting what we know—and don’t know—about dietary changes during GLP-1 therapy. It also uncovers critical gaps in research and discusses why understanding these changes is essential for improving patient outcomes.
The original article, "Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs," was published in Obesity Pillars in July 2024.
Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024 Jul 25;11:100121. doi: 10.1016/j.obpill.2024.100121. Erratum in: Obes Pillars. 2024 Oct 02;12:100136. doi: 10.1016/j.obpill.2024.100136.
You and your colleagues can stay connected to ANHI and events by subscribing to our monthly newsletter and other electronic communications.
Stay connected